Covid-19: why mix and match vaccines?

Loading player...
The Com-Cov trial run by the Oxford Vaccine Group in the UK will be testing the efficacy and safety of a ‘mix and match’ approach to immunisation. By giving some participants either the Pfizer/BioNTech or Oxford/AstraZeneca vaccine, and a second dose of the other, the trial aims to find out if combining different jabs offers sufficient protection. Sarah Boseley speaks to Dr Peter English about where this technique has been used in the past, why it could be beneficial, and how mixing vaccines actually works. Help support our independent journalism at theguardian.com/sciencepod
16 Feb 2021 English United Kingdom Science · Nature

Other recent episodes

‘Ferritin face’: can you really diagnose low iron from a selfie?

Social media is awash with claims iron deficiency can be identified in the mirror by dark circles, breaking hair and dry skin. But is ‘ferritin face’ real? Madeleine Finlay tells Ian Sample why so many of us struggle to keep our iron levels up, how we can actually diagnose low…
5 Nov 21 min

How a scientist went from hero to traitor in a US water crisis

When the water in Flint, Michigan, became contaminated with dangerous levels of lead, Dr Siddhartha Roy, then a third year PhD student, was part of the team of scientists who publicly contradicted state and federal claims that it was safe. He became a local hero until a new piece of…
3 Nov 18 min

Perimenopause is everywhere. How do you know if you’re in it?

Perimenopause has become a hot topic, with celebrities sharing their experiences and doctors offering tips and advice online. But despite the benefits of growing awareness, a rising number of women are now encountering misinformation about treatments such as HRT. Madeleine Finlay hears from Dr Paula Briggs, a consultant in sexual…
27 Oct 15 min

Elizabeth Holmes is back in the spotlight: why can’t we look away?

You Can See Everything, a documentary about the disgraced biotech company founder Elizabeth Holmes, has enjoyed a record-breaking opening in the US. It is a testament to how fascinated we remain by the convicted fraudster, but what is behind the enduring appeal? US technology editor Blake Montgomery tells Madeleine Finlay…
22 Oct 17 min